Starling Oncology (STLNW) Non-Current Deferred Tax Liability (2020 - 2025)

Starling Oncology (STLNW) has reported Non-Current Deferred Tax Liability for 6 consecutive years, with $7.8 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Deferred Tax Liability fell 15.76% year-over-year to $7.8 million; the trailing twelve-month figure through Dec 2025 stood at $7.8 million (down 15.76% YoY), and the FY2025 full-year result was $7.8 million, down 15.76% from the prior year.
• Non-Current Deferred Tax Liability rose to $7.8 million in Q4 2025 per STLNW's latest filing, from $32000.0 in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $10.2 million in Q4 2023 and bottomed at $32000.0 in Q1 2024.
• Historically, Non-Current Deferred Tax Liability has averaged $2.7 million across 5 years, with a median of $502000.0 in 2022.
• The sharpest annual moves came in 2022 and 2023: Non-Current Deferred Tax Liability soared 327.84% in 2022, then tumbled 85.12% in 2023.
• Over 5 years, Non-Current Deferred Tax Liability stood at $2.0 million in 2021, then surged by 327.84% to $8.7 million in 2022, then increased by 17.38% to $10.2 million in 2023, then fell by 9.7% to $9.2 million in 2024, then declined by 15.76% to $7.8 million in 2025.
• According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $7.8 million, $32000.0, and $9.2 million for Q4 2025, Q1 2025, and Q4 2024 respectively.